Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

Bell Potter has given its take on this fallen giant. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to ...

At five minutes past 4 o’clock on Tuesday afternoon, one of the country’s largest listed companies and an absolute ASX stalwart announced to the sharemarket that its chief executive had resigned. The ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

PCWorld reports that Qualcomm’s Snapdragon X2 Elite chip outperforms Apple’s M5 in real-world tests like Handbrake and Blender rendering tasks. The new chip shows significant gaming improvements over ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

Given its struggles over the past couple of years, it has been tempting to sell CSL Ltd (ASX: CSL) shares on numerous occasions. However, I'm hoping to never sell the biotechnology giant's shares. The ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) will be reporting earnings this Tuesday after market close. Here’s what investors should know. Carlisle beat analysts’ revenue ...